JILIN AODONG(SZ:000623)2022-12-10 08:04Group 1: Company Strategy and Development - The company will continue to focus on the pharmaceutical industry while investing in other financial sectors to generate substantial investment returns, which will be reinvested into the core business [2][3] - Currently, the company has 7 specialized pharmaceutical subsidiaries, expanding from a single entity to multiple entities through mergers and acquisitions [3] - The company aims to enhance product quality through increased hardware and software investments and modern marketing strategies to boost sales [3] Group 2: Product and Market Focus - The company follows a "large variety, multiple varieties" strategy, focusing on major products like Anshen Bnnao Liquid and Ribose Injection II to drive the growth of other products [3] - Jilin Province is a major ginseng production area, with the Yanbian region accounting for 40% of the province's output; the company has developed a specialized subsidiary for ginseng research and production [3] - The company is currently in the market promotion phase for its collaboration with Japan on the Takao enzyme project [3] Group 3: Management and Performance - Company executives have increased their holdings, believing the stock price is undervalued and expressing confidence in the company's future [3] - The company has implemented a series of regulations for subsidiary management, including performance assessments based on sales revenue, profit, inventory, accounts receivable, and sales expenses [3] - The growth of chemical drugs in recent years is attributed to positive impacts from national pharmaceutical reforms and market recognition of the company's product quality and efficacy [3]